These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 33355290

  • 21. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C, Pellom ST, Morillon Ii YM, Schlom J, Jochems C.
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [Abstract] [Full Text] [Related]

  • 22. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
    Chen M, Xiang R, Wen Y, Xu G, Wang C, Luo S, Yin T, Wei X, Shao B, Liu N, Guo F, Li M, Zhang S, Li M, Ren K, Wang Y, Wei Y.
    Sci Rep; 2015 Sep 23; 5():14421. PubMed ID: 26394925
    [Abstract] [Full Text] [Related]

  • 23. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May 23; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 24. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K, Miyakawa R, Suzuki K, Narumi K, Udagawa T, Yamamoto Y, Chikaraishi T, Yoshida T, Aoki K.
    Cancer Sci; 2014 Feb 23; 105(2):159-67. PubMed ID: 24289533
    [Abstract] [Full Text] [Related]

  • 25. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 26. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE, Mauze S, Joyce-Shaikh B, Xia J, Bowman EP, Beebe AM, Cua DJ, Jain R.
    Cancer Res; 2017 Mar 01; 77(5):1108-1118. PubMed ID: 28122327
    [Abstract] [Full Text] [Related]

  • 27. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
    Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW.
    PLoS One; 2013 Mar 01; 8(7):e70417. PubMed ID: 23894654
    [Abstract] [Full Text] [Related]

  • 28. Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model.
    Liu JJ, Su QD, Yi Y, Shen LP, Bi SL.
    Biomed Environ Sci; 2024 Feb 20; 37(2):187-195. PubMed ID: 38582981
    [Abstract] [Full Text] [Related]

  • 29. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM, Schlom J, Hodge JW.
    Cancer Res; 2002 Oct 15; 62(20):5770-7. PubMed ID: 12384537
    [Abstract] [Full Text] [Related]

  • 30. Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.
    Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Dirmeier U, Steigerwald R, Giffon T, Laus R, Delcayre A.
    Cancer Immunol Immunother; 2012 Jan 15; 61(1):19-29. PubMed ID: 21822917
    [Abstract] [Full Text] [Related]

  • 31. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C, Schlom J, Hodge JW.
    Clin Cancer Res; 2005 Mar 15; 11(6):2416-26. PubMed ID: 15788693
    [Abstract] [Full Text] [Related]

  • 32. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
    Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H.
    Cancer Gene Ther; 2004 Oct 15; 11(10):665-80. PubMed ID: 15354200
    [Abstract] [Full Text] [Related]

  • 33. IL-7/αIL-7 mAb M25 immunocomplexes expand CD8+ T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage.
    Hrabos D, Hnizdilova T, Tomala J, Uhlik J, Kovar M.
    Cytokine; 2020 Sep 15; 133():155174. PubMed ID: 32599539
    [Abstract] [Full Text] [Related]

  • 34. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S.
    PLoS One; 2014 Sep 15; 9(2):e89350. PubMed ID: 24586709
    [Abstract] [Full Text] [Related]

  • 35. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
    Kalim KW, Yang JQ, Wunderlich M, Modur V, Nguyen P, Li Y, Wen T, Davis AK, Verma R, Lu QR, Jegga AG, Zheng Y, Guo F.
    J Immunother Cancer; 2022 Nov 15; 10(11):. PubMed ID: 36427906
    [Abstract] [Full Text] [Related]

  • 36. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.
    Clin Cancer Res; 2010 May 15; 16(10):2781-91. PubMed ID: 20460483
    [Abstract] [Full Text] [Related]

  • 37. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO, Chin D, Smith MA, Luistro LL, Snyder LA.
    Oncotarget; 2017 Jun 13; 8(24):39117-39130. PubMed ID: 28388572
    [Abstract] [Full Text] [Related]

  • 38. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N.
    Cancer; 2007 Oct 01; 110(7):1469-77. PubMed ID: 17685394
    [Abstract] [Full Text] [Related]

  • 39. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST, Saung MT, Blair AB, Henderson MG, Thomas DL, Zheng L.
    Cancer Lett; 2021 Feb 28; 499():99-108. PubMed ID: 33271264
    [Abstract] [Full Text] [Related]

  • 40. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL.
    Vaccine; 2006 Jun 05; 24(23):4975-86. PubMed ID: 16621183
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.